Aardvark Therapeutics, Inc. (AARD) · Oct 22, 2026 · Other events
Clinical hold lifted — FDA lifted the clinical hold on ARD-101’s IND
Aardvark’s FDA clinical-hold lift reopens ARD-101 development in Prader-Willi syndrome, but a new Phase 3 design and trial data remain ahead.
Aardvark is a clinical-stage biotech whose lead program, ARD-101, had been stalled after reversible ECG findings triggered a February dosing pause, a May FDA clinical hold, and eventual termination of the HERO and OLE trials. By August 11, 2026, the company was still assessing the unblinded data and working with the FDA on a path forward.
The main setback is no longer a full regulatory stop. The FDA has lifted the clinical hold after Aardvark completed additional ECG testing and an in-vitro cardiac sodium-channel study; the company says no cardiac events were observed in the new ECG study at 200 mg and 400 mg twice daily. 〔0〕 That materially advances the business story versus the pre-filing situation because ARD-101 can move back toward clinical development rather than remaining frozen.
This is permission to redesign the program, not a restart of the original Phase 3 trial. Aardvark says it plans to resume development only after further FDA engagement and alignment on the Phase 3 design. 〔1〕 The earlier HERO and OLE studies were terminated, so the company still faces a new protocol, added time, and uncertainty over how much of the accumulated data can support the next trial.
The safety cloud is reduced but not erased, while efficacy remains the next major question. The hold followed reversible ECG changes in healthy volunteers, and tomorrow’s webcast will review data from the terminated HERO and OLE trials rather than deliver a clean, prospectively powered Phase 3 result. 〔2〕 The filing itself gives no efficacy numbers, and it acknowledges that the terminated studies were not powered to assess efficacy.
Bottom line: The FDA lift removes the most immediate regulatory roadblock and reopens ARD-101’s path in Prader-Willi syndrome. It is meaningfully better than the hold remaining in place, but the program still needs a new Phase 3 design and credible efficacy evidence before the recovery is complete.
Investor webcast reviewing HERO/OLE data, October 23
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!